Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

PURPOSE: The phase III DATA study compared 6 and 3 years of adjuvant anastrozole following 2–3 years of tamoxifen in postmenopausal breast cancer patients. This pre-planned side-study assessed the relationship between a reduced bone mineral density (BMD) and distant recurrence-free survival (DRFS),...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hellemond, Irene E. G., Smorenburg, Carolien H., Peer, Petronella G. M., Swinkels, Astrid C. P., Seynaeve, Caroline M., van der Sangen, Maurice J. C., Kroep, Judith R., de Graaf, Hiltje, Honkoop, Aafke H., Erdkamp, Frans L. G., van den Berkmortel, Franchette W. P. J., de Roos, Wilfred K., Linn, Sabine C., Imholz, Alexander L. T., de Boer, Maaike, Tjan-Heijnen, Vivianne C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103013/
https://www.ncbi.nlm.nih.gov/pubmed/32124136
http://dx.doi.org/10.1007/s10549-020-05567-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103013/
https://www.ncbi.nlm.nih.gov/pubmed/32124136
http://dx.doi.org/10.1007/s10549-020-05567-9

Ejemplares similares